Expands Otsuka portfolio in psychiatric and neurological fields and aims to accelerate development of Transcend's portfolio, including the TSND-201 progr...
Mayo Clinic announces a gift of $75 million from the Thomas and Elizabeth Grainger family to support Bold. Forward. Unbound. in Rochester, Mayo Clinic's ...
Eli Lilly and Company announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekiz...
Thermo Fisher Scientific Inc., the world leader in serving science, announced a strategic collaboration with SHL Medical, a leading provider of advance...
Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has ann...
HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&...
Wilmington PharmaTech (“Wilmington”), a leading U.S.-based research, development, and manufacturing organization (CRDMO) focused on complex c...
Gilead Sciences, Inc. (Nasdaq: GILD) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology...
New “Danaher Beacon,” first in the European Union, aims to accelerate translation, scalability, and reliability across cell and gene therap...
Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world’s largest independent nonprofit research and development o...
New England Biolabs announced the release of the EnClose Cell-free dbDNA Synthesis Kit, developed in collaboration with Touchlight. This novel kit enable...
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrut...
Curia, a leading contract research, development and manufacturing organization (CDMO), announced progress on the expansion at its Glasgow, UK sterile dru...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease prog...
© 2026 Biopharma Boardroom. All Rights Reserved.
